Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HRC 101

Drug Profile

HRC 101

Alternative Names: HML 109

Latest Information Update: 13 Sep 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hemosol Corp
  • Developer Hemosol BioPharma
  • Class
  • Mechanism of Action Oxygen carriers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Anaemia

Most Recent Events

  • 05 Sep 2007 Hemosol is seeking funding, co-development and/or out-licensing opportunities for HRC 101 (http://www.hemosol.com/)
  • 19 Jul 2007 Hemosol Corp. is now a wholly-owned subsidiary of Catalyst Fund Ltd. Partnership II; the pharmaceutical business will be known as Hemosol BioPharma Inc.
  • 26 Aug 2005 HRC 101 is still available for licensing (http://www.hemosol.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top